Endometriosis Clinical Trials

Find Endometriosis Clinical Trials Near You

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 24-Week Treatment Period and a 28-Week Extension

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 49
Healthy Volunteers: f
View:

• 1\. Premenopausal female subjects, between 18 and 49 years of age, inclusive.

• 2\. Has a surgical diagnosis of endometriosis (laparoscopy or laparotomy) as documented by medical records within 10 years before screening.

• 3\. Has a Composite Pelvic Signs and Symptoms Score total score of ≥ 6 at screening with a score of at least 2 for DYS and at least 2 for NMPP.

• 4\. Subject has reported moderate or severe for her endometriosis-associated DYS AND NMPP before randomization.

• 5\. Subject has at least two consecutive regular menstrual cycle (i.e. 21 to 35 days in duration) prior to randomization.

• 6\. Subject agrees to use required (nonhormonal) birth control methods during the entire length of participation in the study and agrees to avoid pregnancy from signing the informed consent until 12 weeks after the last dose.

• 7\. Subject agrees to use only those rescue analgesic medications permitted by the protocol during the Screening, Treatment and Posttreatment follow-up Periods for her endometriosis-associated pain.

• 8\. Criteria for Extension Treatment Period:Subject who completes treatment of the placebo-controlled double-blind treatment period and assessments at Week 24.

Locations
Other Locations
China
Peking Union Medical College Hospital
NOT_YET_RECRUITING
Beijing
Nanjing Women and children's healthcare hospital
NOT_YET_RECRUITING
Nanning
The International Peace Maternity and Child Health Hospital of the China Welfare Institute
NOT_YET_RECRUITING
Shanghai
Second Affiliated Hospital of Soochow University
RECRUITING
Suzhu
Tianjin Medical University General Hospital
NOT_YET_RECRUITING
Tianjin
Contact Information
Primary
Xu Yeqing
yeqing.xu@hopemedinc.com
86-18717858198
Time Frame
Start Date: 2026-01-29
Estimated Completion Date: 2028-09-01
Participants
Target number of participants: 540
Treatments
Experimental: HMI-115_120mg
120mg, Once Every 2 weeks, subcutaneously injection,total of 26 injections (Week 0 to Week 52) or total of 14 injections (Week 24 to Week 52/Extension Treatment Period of Placebo )
Experimental: HMI-115_240mg
240mg, Once Every 2 weeks, subcutaneously injection,total of 26 injections (Week 0 to Week 52) or total of 14 injections (Week 24 to Week 52/Extension Treatment Period of Placebo )
Placebo_comparator: Placebo
2ml , Once Every 2 weeks, subcutaneously injection,total of 12 injections (Week 0 to Week 24)
Related Therapeutic Areas
Sponsors
Leads: Hope Medicine (Nanjing) Co., Ltd

This content was sourced from clinicaltrials.gov